An observational study in Cytomegalovirus Infections, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 23 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Cytomegalovirus Infections with a site in Italy — 5 open to participants now, 6 under way, 1 of them phase 3. Cytomegalovirus Infections · Italy.
Among the 18 studies in Cytomegalovirus Infections with a site in Italy, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 13th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →5 of the 18 studies in Cytomegalovirus Infections with a site in Italy are open now. Recruiting first, the newest first:
Antonello Di Paolo, M.D., Ph.D. · Sites in Italy
Ages 1 mo–18 yrs
MSD Italia S.r.l. · Sites in Italy
Ages 0–18
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+
Tobias Feuchtinger · Sites in Italy, Belgium, France and 3 more countries
Ages 2 mo+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 10 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 93 observational studies indexed under Cytomegalovirus Infections.
Median enrollment 326 across the 14 interventional studies, 177 across the 4 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 18 have an industry lead sponsor. The 10 most frequent:
IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 517 studies on the registry; 292 are open to participants now.
IRCCS Azienda Ospedaliero-Universitaria di Bologna has 1 study filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Cytomegalovirus Infections with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05234723IRCCS Azienda Ospedaliero-Universitaria di BolognaGanciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Cytomegalovirus Infections with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.
Cytomegalovirus (CMV) is an important cause of morbidity and mortality in solid organ transplant (SOT) patients and hematopoietic stem cell transplant (HSCT) patients. Ganciclovir (GCV) is the first line therapy for treatment and prevention of CMV infection in SOT and HSCT recipients, with established efficacy and relatively safe profile.
Ganciclovir-resistant or refractory (GCV-RR) CMV is an uncommon but frightening clinical problem due to limited, toxic and less effective therapeutic alternative drugs. Indeed, some studies indicate that GCV-RR is associated with significant additional attributable morbidity and mortality in SOT and HSCT recipients compared with ganciclovir susceptible (GCV-S) CMV disease.
Few data are available about the incidence of GCV-RR-CMV in SOT and HSCT patients showing a range from 0% to 3% . The serological mismatch group and the type of SOT have been reported as the main factors influencing such range. Indeed, in one of the largest experience now available in SOT, the incidence of GCV-resistant (GCV-RT) CMV infection accounted up to 12% in a cohort of lung transplant recipients. Among HSCT patients, haploidentical, allogeneic unrelated, and cord blood HSCT have been associated with increased risk of GCV-RR CMV infection. Among risk factors for GCV-RR, high-risk D/R subset (R- in SOT and R+ in HSCT), high viral loads, inadequate drug delivery, increased durations of antiviral drug exposure and the use of more potent immunosuppressive regimens have been reported. However, these reports come from small, monocentric experiences with a limited number of cases, providing a fragmentary picture of the overall burden and epidemiological characteristics of GCV-RR in transplant patients. Information of the epidemiological background of GCV-RR after transplantation could be helpful in improving preventive management and reducing the emergence of GCV-RT episodes. Indeed, studies investigating viral genetic alterations showed that mutations conferring ganciclovir resistance are not present at baseline but emerge and become amplified over time, especially in the presence of an incompletely suppressive drug exposure. The GCV-RT is due to mutations in UL97 and UL54 genes. UL97 mutations confer various degrees of phenotypic resistance to ganciclovir. Mutations in UL54 determine higher-level resistance to ganciclovir and usually appear as a second step after mutations in UL97.
The investigators carry-out a multicenter retrospective observational study to define incidence of GCV-RR CMV-infection in SOT and HSCT patients and to identify the risk factors for its development in SOT and HSCT recipients. Data from this study could be useful to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.
All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC during the study period will be screened for inclusion according to inclusion and exclusion criteria. Eligible patients will be classified as cases or controls according to the following definitions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Solid Organ Transplant (SOT) and Hematopoietic Stem Cell Transplant (HSCT) patients with Ganciclovir Resistant or Refractory Cytomegalovirus infection
To define incidence of GCV-RR CMV-infection in SOT and HSCT patients
To define incidence of GCV-RR CMV-infection in SOT and HSCT patients
Time frame: Through study completion, an average of 1 year
To define the risk factors for GCV-RR CMV-infection development in SOT and HSCT patients
To define the risk factors for GCV-RR CMV-infection development in SOT and HSCT patients
Time frame: Through study completion, an average of 1 year
To compare type of CMV episode between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
To compare type of CMV episode: infection or disease (the last cathegorized as CMV syndrome or Tissue invasion) between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
Time frame: Through study completion, an average of 1 year
To compare virological cure between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
To compare virological cure at 30, 60 and 90 days after CMV infection diagnosis and relapse of CMV infection between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
Time frame: Through study completion, an average of 1 year
To compare clinical cure between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
To compare clinical cure at 30, 60 and 90 days after CMV infection diagnosis between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
Time frame: Through study completion, an average of 1 year
To compare graft outcome between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
To compare graft failure rate and the need of re-transplant between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
Time frame: Through study completion, an average of 1 year
To compare the need of ICU and hospital stay between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
To compare total length of ICU and hospital stay between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
Time frame: Through study completion, an average of 1 year
To compare the need of readmission in ICU and/or hospital between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
To compare the need of readmission in ICU and/or hospital between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
Time frame: Through study completion, an average of 1 year
To compare all-cause mortality between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
To compare all-cause mortality during infection episode and follow-up (30, 60, 90 days after the first CMV infection diagnosis) between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection
Time frame: Through study completion, an average of 1 year
To describe the therapeutic management of GCV-RR CMV-infection
To describe the therapeutic management of GCV-RR CMV-infection including the use of CMV-specific T-cell assay
Time frame: Through study completion, an average of 1 year
Started Jun 2023 (actual). Primary completion is estimated for Feb 2027, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna →